Conference Coverage: ASH 2022 – Focus on Multiple Myeloma
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding multiple myeloma.
Faculty Members
Keith Stewart, MB, ChB, MBA
Princess Margaret Cancer Centre, Toronto, ON, Canada
Gareth Morgan, MD, PhD, FRCP, FRCPath
Perlmutter Cancer Center, New York, NY, USA
Irene M. Ghobrial, MD
Dana-Farber Cancer Institute, Boston, MA, USA
Suzanne Lentzsch, MD, PhD
Columbia University Irving Medical Center, New York, NY, USA
Peter Voorhees, MD
Levine Cancer Institute, Charlotte, NC, USA
Maria-Victoria Mateos, MD, PhD
University of Salamanca, Spain
Hermann Einsele, MD, FRCP
University of Würzburg, Germany
REPORT BACKGROUND
- Clinical experts from across the world will discuss global perspectives on current treatment strategies and emerging therapies in multiple myeloma derived from ASH 2022 data
- The goal of the expert panel will be to critique and debate new evidence in multiple myeloma and gain strategic insight into the most impactful abstracts from the ASH meeting with respect to shaping current research directions and/or changing the scope of practical clinical care